Tapewire

Nasdaq · USD

BCRX

BIOCRYST PHARMACEUTICALS INC

Export transactions ↓
Tapewire entity
315
SEC CIK
0000882796
Parsed reports
483

Last 12 months

Inside the activity.

0 purchase rows · 10 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202501
Dec 202505
Jan 202600
Feb 202600
Mar 202602
Apr 202600
May 202602
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
August 31, 2026 Filed Sep 2, 2026 20:16 UTC GrantCommon Stock 644 $9.70 $6,246.80
Disclosure

SEC source: 0000882796-26-000065 · form4.xml · nonDerivative · entry 1

Stonehouse Jon P · CIK 0001385496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,340,419

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.

Read SEC document
August 31, 2026 Filed Sep 2, 2026 20:13 UTC GrantCommon Stock 1,288 $9.70 $12,493.60
Disclosure

SEC source: 0000882796-26-000063 · form4.xml · nonDerivative · entry 1

Milne Jill C. · CIK 0001644246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,226

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.

Read SEC document
August 31, 2026 Filed Sep 2, 2026 20:10 UTC GrantCommon Stock 1,159 $9.70 $11,242.30
Disclosure

SEC source: 0000882796-26-000061 · form4.xml · nonDerivative · entry 1

MILANO VINCENT · CIK 0001187159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,642

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500.

Read SEC document
August 31, 2026 Filed Sep 2, 2026 20:06 UTC
McKee Amy EDirector
GrantCommon Stock 644 $9.70 $6,246.80
Disclosure

SEC source: 0000882796-26-000059 · form4.xml · nonDerivative · entry 1

McKee Amy E · CIK 0001883764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,821

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.

Read SEC document
August 31, 2026 Filed Sep 2, 2026 20:04 UTC
Frank StevenDirector
GrantCommon Stock 1,288 $9.70 $12,493.60
Disclosure

SEC source: 0000882796-26-000057 · form4.xml · nonDerivative · entry 1

Frank Steven · CIK 0001583886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,747

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:32 UTC GrantAutomatic Stock Option Grant · Derivative 33,540 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0000882796-26-000055 · form4.xml · derivative · entry 2

Milne Jill C. · CIK 0001644246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,540

Underlying: Common Stock · 33,540 shares

Expires 2036-06-11

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:32 UTC GrantCommon Stock 15,294 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000055 · form4.xml · nonDerivative · entry 1

Milne Jill C. · CIK 0001644246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,938

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:30 UTC GrantAutomatic Stock Option Grant · Derivative 33,540 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0000882796-26-000053 · form4.xml · derivative · entry 3

Galson Steven K · CIK 0001495328 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,540

Underlying: Common Stock · 33,540 shares

Expires 2036-06-11

F3 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:30 UTC GrantCommon Stock 15,294 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000053 · form4.xml · nonDerivative · entry 1

Galson Steven K · CIK 0001495328 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,794

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:16 UTC
Frank StevenDirector
GrantAutomatic Stock Option Grant · Derivative 33,540 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0000882796-26-000045 · form4.xml · derivative · entry 2

Frank Steven · CIK 0001583886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,540

Underlying: Common Stock · 33,540 shares

Expires 2036-06-11

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:16 UTC
Frank StevenDirector
GrantCommon Stock 15,294 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000045 · form4.xml · nonDerivative · entry 1

Frank Steven · CIK 0001583886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,459

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:29 UTC
LEVIN ALAN GDirector
GrantAutomatic Stock Option Grant · Derivative 33,540 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0000882796-26-000052 · form4.xml · derivative · entry 2

LEVIN ALAN G · CIK 0001174452 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,540

Underlying: Common Stock · 33,540 shares

Expires 2036-06-11

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:29 UTC
LEVIN ALAN GDirector
GrantCommon Stock 15,294 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000052 · form4.xml · nonDerivative · entry 1

LEVIN ALAN G · CIK 0001174452 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,565

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:14 UTC GrantAutomatic Stock Option Grant · Derivative 33,540 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0000882796-26-000043 · form4.xml · derivative · entry 2

SANDERS MACHELLE · CIK 0001718020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,540

Underlying: Common Stock · 33,540 shares

Expires 2036-06-11

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:14 UTC GrantCommon Stock 15,294 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000043 · form4.xml · nonDerivative · entry 1

SANDERS MACHELLE · CIK 0001718020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,936

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:12 UTC GrantAutomatic Stock Option Grant · Derivative 33,540 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0000882796-26-000041 · form4.xml · derivative · entry 2

MILANO VINCENT · CIK 0001187159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,540

Underlying: Common Stock · 33,540 shares

Expires 2036-06-11

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:12 UTC GrantCommon Stock 15,294 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000041 · form4.xml · nonDerivative · entry 1

MILANO VINCENT · CIK 0001187159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,483

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:10 UTC GrantAutomatic Stock Option Grant · Derivative 33,540 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0000882796-26-000039 · form4.xml · derivative · entry 4

Stonehouse Jon P · CIK 0001385496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,540

Underlying: Common Stock · 33,540 shares

Expires 2036-06-11

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:10 UTC GrantCommon Stock 15,294 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000039 · form4.xml · nonDerivative · entry 1

Stonehouse Jon P · CIK 0001385496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,339,775

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:06 UTC GrantAutomatic Stock Option Grant · Derivative 33,540 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0000882796-26-000035 · form4.xml · derivative · entry 2

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,540

Underlying: Common Stock · 33,540 shares

Expires 2036-06-11

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:06 UTC GrantCommon Stock 15,294 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000035 · form4.xml · nonDerivative · entry 1

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,646

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:08 UTC
McKee Amy EDirector
GrantAutomatic Stock Option Grant · Derivative 33,540 $0.00 Strike: $8.50 $0.00
Disclosure

SEC source: 0000882796-26-000037 · form4.xml · derivative · entry 2

McKee Amy E · CIK 0001883764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,540

Underlying: Common Stock · 33,540 shares

Expires 2036-06-11

F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Read SEC document
June 11, 2026 Filed Jun 15, 2026 20:08 UTC
McKee Amy EDirector
GrantCommon Stock 15,294 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000037 · form4.xml · nonDerivative · entry 1

McKee Amy E · CIK 0001883764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,177

F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:16 UTC GrantCommon Stock 1,262 $8.91 $11,244.42
Disclosure

SEC source: 0000882796-26-000033 · form4.xml · nonDerivative · entry 1

Milne Jill C. · CIK 0001644246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,644

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:14 UTC GrantCommon Stock 631 $8.91 $5,622.21
Disclosure

SEC source: 0000882796-26-000031 · form4.xml · nonDerivative · entry 1

Stonehouse Jon P · CIK 0001385496 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,324,481

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:11 UTC
McKee Amy EDirector
GrantCommon Stock 631 $8.91 $5,622.21
Disclosure

SEC source: 0000882796-26-000029 · form4.xml · nonDerivative · entry 1

McKee Amy E · CIK 0001883764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,883

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:08 UTC GrantCommon Stock 1,122 $8.91 $9,997.02
Disclosure

SEC source: 0000882796-26-000027 · form4.xml · nonDerivative · entry 1

MILANO VINCENT · CIK 0001187159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,189

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $20,000.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 20:05 UTC
Frank StevenDirector
GrantCommon Stock 1,262 $8.91 $11,244.42
Disclosure

SEC source: 0000882796-26-000025 · form4.xml · nonDerivative · entry 1

Frank Steven · CIK 0001583886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,165

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

Read SEC document
May 18, 2026 Filed May 19, 2026 20:07 UTC
McKee Amy EDirector
SaleCommon Stock 11,180 $8.97 $100,284.60
Disclosure

SEC source: 0000882796-26-000023 · form4.xml · nonDerivative · entry 1

McKee Amy E · CIK 0001883764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,252

F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.96 to $8.985. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
May 13, 2026 Filed May 15, 2026 20:08 UTC
Barnes Alane PChief Legal Officer
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 62,500 $0.00 Strike: $5.04 $0.00
Disclosure

SEC source: 0000882796-26-000021 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 62,500 shares

Expires 2027-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F2 · derivative.exercise_date: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.

Read SEC document
May 13, 2026 Filed May 15, 2026 20:08 UTC
Barnes Alane PChief Legal Officer
SaleCommon Stock 62,500 $9.54 $596,250.00
Disclosure

SEC source: 0000882796-26-000021 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 400,703

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
May 13, 2026 Filed May 15, 2026 20:08 UTC
Barnes Alane PChief Legal Officer
Exercise / conversionCommon Stock 62,500 $5.04 $315,000.00
Disclosure

SEC source: 0000882796-26-000021 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 463,203

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
April 06, 2026 Filed Apr 7, 2026 20:24 UTC
Menon SandeepChief R&D Officer
GrantEmp. Stock Option (Right to Buy) · Derivative 441,350 $0.00 Strike: $9.47 $0.00
Disclosure

SEC source: 0000882796-26-000019 · form4.xml · derivative · entry 2

Menon Sandeep · CIK 0002123967 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 441,350

Underlying: Common Stock · 441,350 shares

Expires 2036-04-06

F2 · shares: Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

F2 · derivative.exercise_date: Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
April 06, 2026 Filed Apr 7, 2026 20:24 UTC
Menon SandeepChief R&D Officer
GrantCommon Stock 205,150 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000019 · form4.xml · nonDerivative · entry 1

Menon Sandeep · CIK 0002123967 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,150

F1 · shares: Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Read SEC document
March 20, 2026 Filed Mar 24, 2026 20:02 UTC Exercise / conversionAutomatic Stock Option Grant · Derivative 49,933 $0.00 Strike: $6.30 $0.00
Disclosure

SEC source: 0000882796-26-000017 · form4.xml · derivative · entry 3

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 49,933 shares

Expires 2034-06-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 20, 2026 Filed Mar 24, 2026 20:02 UTC SaleCommon Stock 49,933 $10.11 $504,822.63
Disclosure

SEC source: 0000882796-26-000017 · form4.xml · nonDerivative · entry 2

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,352

F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.09 to $10.14. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
March 20, 2026 Filed Mar 24, 2026 20:02 UTC Exercise / conversionCommon Stock 49,933 $6.30 $314,577.90
Disclosure

SEC source: 0000882796-26-000017 · form4.xml · nonDerivative · entry 1

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,285

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:11 UTC
Barnes Alane PChief Legal Officer
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 150,000 $0.00 Strike: $5.51 $0.00
Disclosure

SEC source: 0000882796-26-000015 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires 2027-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F3 · derivative.exercise_date: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:11 UTC
Barnes Alane PChief Legal Officer
SaleCommon Stock 150,000 $9.15 $1,372,500.00
Disclosure

SEC source: 0000882796-26-000015 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 400,703

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.95 to $9.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:11 UTC
Barnes Alane PChief Legal Officer
Exercise / conversionCommon Stock 150,000 $5.51 $826,500.00
Disclosure

SEC source: 0000882796-26-000015 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 550,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 21:34 UTC Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative 305,995 $0.00 Strike: $3.22 $0.00
Disclosure

SEC source: 0000882796-26-000011 · form4.xml · derivative · entry 6

Stonehouse Jon P · CIK 0001385496 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 305,995 shares

Expires 2026-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 21:34 UTC Disposition to issuerCommon Stock 305,995 $8.64 $2,643,796.80
Disclosure

SEC source: 0000882796-26-000011 · form4.xml · nonDerivative · entry 3

Stonehouse Jon P · CIK 0001385496 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,323,850

F2 · shares: This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 21:34 UTC Exercise / conversionCommon Stock 305,995 $3.22 $985,303.90
Disclosure

SEC source: 0000882796-26-000011 · form4.xml · nonDerivative · entry 2

Stonehouse Jon P · CIK 0001385496 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,629,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:36 UTC GrantCommon Stock 528 $8.75 $4,620.00
Disclosure

SEC source: 0000882796-26-000013 · form4.xml · nonDerivative · entry 1

Milne Jill C. · CIK 0001644246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,382

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the prorated quarterly cash Board Member retainer of $4,625.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:34 UTC GrantCommon Stock 421 $8.75 $3,683.75
Disclosure

SEC source: 0000882796-26-000011 · form4.xml · nonDerivative · entry 1

Stonehouse Jon P · CIK 0001385496 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,323,850

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:30 UTC GrantCommon Stock 848 $8.75 $7,420.00
Disclosure

SEC source: 0000882796-26-000009 · form4.xml · nonDerivative · entry 1

MILANO VINCENT · CIK 0001187159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,067

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250 and, effective January 23, 2026, in lieu of 50% of the quarterly cash Board Chair retainer of $20,000.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:29 UTC
Frank StevenDirector
GrantCommon Stock 1,285 $8.75 $11,243.75
Disclosure

SEC source: 0000882796-26-000007 · form4.xml · nonDerivative · entry 1

Frank Steven · CIK 0001583886 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,903

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:25 UTC
McKee Amy EDirector
GrantCommon Stock 642 $8.75 $5,617.50
Disclosure

SEC source: 0000882796-26-000005 · form4.xml · nonDerivative · entry 1

McKee Amy E · CIK 0001883764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,432

F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.

Read SEC document
January 23, 2026 Filed Jan 27, 2026 22:22 UTC GrantAutomatic Stock Option Grant · Derivative 26,684 $0.00 Strike: $6.79 $0.00
Disclosure

SEC source: 0000882796-26-000003 · form4.xml · derivative · entry 3

Milne Jill C. · CIK 0001644246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,684

Underlying: Common Stock · 26,684 shares

Expires 2036-01-23

F3 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

F4 · derivative.exercise_date: The option grant vests 1/36 per month over a 3-year period measured from the date of grant.

Read SEC document
January 23, 2026 Filed Jan 27, 2026 22:22 UTC GrantCommon Stock 12,272 $0.00 $0.00
Disclosure

SEC source: 0000882796-26-000003 · form4.xml · nonDerivative · entry 2

Milne Jill C. · CIK 0001644246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,854

F2 · shares: Automatic non-employee director grant of restricted stock units pursuant to the BioCryst Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest in three equal annual installments beginning on the twelve-month anniversary of the date of grant.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.